- Home
- CDNA
CDNA
CareDx Inc.
as 04-11-2025 4:00pm EST
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 1.1B | IPO Year: | 2014 |
| Target Price: | $29.43 | AVG Volume (30 days): | 680.6K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.42 - $34.84 | Next Earning Date: | 04-30-2025 |
| Revenue: | $333,785,000 | Revenue Growth: | 19.07% |
| Revenue Growth (this year): | 13.33% | Revenue Growth (next year): | 15.07% |
Stock Insider Trading Activity of CareDx Inc. (CDNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jain Abhishek | CDNA | Chief Financial Officer | Apr 7 '25 | Sell | $17.72 | 265 | $4,695.80 | 337,418 | |
| Novack Jeffrey Adam | CDNA | Secretary and General Counsel | Apr 7 '25 | Sell | $17.72 | 924 | $16,373.28 | 126,911 | |
| Bickerstaff George | CDNA | Director | Mar 10 '25 | Sell | $18.36 | 20,000 | $367,102.00 | 103,027 | |
| Novack Jeffrey Adam | CDNA | Secretary and General Counsel | Feb 3 '25 | Sell | $23.30 | 3,512 | $81,829.25 | 126,911 |
Latest CareDx Inc. News
CDNA Breaking Stock News: Dive into CDNA Ticker-Specific Updates for Smart Investing
Argus Research
4 days ago
Daily – Vickers Top Buyers & Sellers for 04/10/2025
Business Wire
6 days ago
CareDx to Report First Quarter 2025 Financial Results
Zacks
9 days ago
Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock?
Business Wire
a month ago
CareDx Launches Two Expanded Indications for AlloSure Testing Services
Simply Wall St.
a month ago
Statutory Earnings May Not Be The Best Way To Understand CareDx's (NASDAQ:CDNA) True Position
Zacks
a month ago
Here's Why Community Health's Florida Divestiture Matters
GuruFocus.com
2 months ago
CareDx Inc (CDNA) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Zacks
2 months ago
CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Compare CDNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDNA CareDx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.